Trials / Completed
CompletedNCT02148640
The NOR-SWITCH Study
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 482 (actual)
- Sponsor
- Diakonhjemmet Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of switching from Remicade to the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis
Conditions
- Rheumatoid Arthritis
- Spondyloarthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Psoriasis Chronic
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Innovator infliximab | |
| DRUG | Biosimilar infliximab |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-06-01
- Completion
- 2017-01-01
- First posted
- 2014-05-28
- Last updated
- 2017-09-25
Locations
30 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT02148640. Inclusion in this directory is not an endorsement.